Celldex Therapeutics’ (CLDX) Buy Rating Reaffirmed at HC Wainwright

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued on Friday, Benzinga reports. They presently have a $64.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 96.38% from the company’s current price.

Other analysts have also issued research reports about the stock. Guggenheim lifted their price objective on shares of Celldex Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Monday, July 20th. Leerink Partners lifted their price target on shares of Celldex Therapeutics from $70.00 to $88.00 and gave the company an “outperform” rating in a research report on Wednesday, September 23rd. Cantor Fitzgerald lifted their price target on shares of Celldex Therapeutics from $61.00 to $72.00 and gave the company an “overweight” rating in a research report on Tuesday, September 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Friday, July 17th. Finally, Wall Street Zen raised shares of Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, July 12th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Celldex Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $61.92.

Celldex Therapeutics Price Performance

Shares of NASDAQ:CLDX traded up $0.94 during mid-day trading on Friday, hitting $32.59. The company had a trading volume of 1,257,848 shares, compared to its average volume of 1,065,756. The firm has a fifty day moving average price of $38.32 and a 200 day moving average price of $34.94. The company has a market capitalization of $2.56 billion, a PE ratio of -7.49 and a beta of 0.90. Celldex Therapeutics has a one year low of $22.10 and a one year high of $45.14.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, beating the consensus estimate of ($1.06) by $0.12. The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.74 million. Research analysts expect that Celldex Therapeutics will post -4.17 earnings per share for the current fiscal year.

Institutional Trading of Celldex Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Handelsbanken Fonder AB raised its holdings in shares of Celldex Therapeutics by 5.0% in the second quarter. Handelsbanken Fonder AB now owns 27,200 shares of the biopharmaceutical company’s stock valued at $1,012,000 after purchasing an additional 1,300 shares during the last quarter. Nykredit A S purchased a new stake in shares of Celldex Therapeutics in the second quarter valued at about $67,000. Arizona State Retirement System raised its holdings in shares of Celldex Therapeutics by 13.0% in the second quarter. Arizona State Retirement System now owns 18,565 shares of the biopharmaceutical company’s stock valued at $691,000 after purchasing an additional 2,139 shares during the last quarter. Intech Investment Management LLC raised its holdings in shares of Celldex Therapeutics by 8.4% in the fourth quarter. Intech Investment Management LLC now owns 33,499 shares of the biopharmaceutical company’s stock valued at $910,000 after purchasing an additional 2,608 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Celldex Therapeutics by 3.5% in the first quarter. The Manufacturers Life Insurance Company now owns 77,772 shares of the biopharmaceutical company’s stock valued at $2,467,000 after purchasing an additional 2,642 shares during the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for diseases with significant unmet medical needs. The company’s research programs target mast cell–mediated disorders, inflammatory diseases, and cancer, using engineered antibodies designed to modulate specific immune-system pathways.

Celldex’s lead product candidate is barzolvolimab, an investigational monoclonal antibody that targets the KIT receptor on mast cells.